PubAg

Main content area

Insulin releasing and alpha-glucosidase inhibitory activity of ethyl acetate fraction of Acorus calamus in vitro and in vivo

Author:
Si, Mei-mei, Lou, Jian-shu, Zhou, Chang-Xin, Shen, Juan-Na, Wu, Hong-Hai, Yang, Bo, He, Qiao-Jun, Wu, Hao-Shu
Source:
Journal of ethnopharmacology 2010 v.128 no.1 pp. 154-159
ISSN:
0378-8741
Subject:
medicinal plants, plant extracts, postprandial state, cell lines, oral administration, roots, inhibitory concentration 50, dose response, alpha-glucosidase, medicinal properties, enzyme inhibition, hormone secretion, blood glucose, enzyme inhibitors, mice, insulin, in vitro studies, Acorus calamus, fractionation, dosage, animal models
Abstract:
Ethnopharmacological relevance: The radix of Acorus calamus L. (AC) is widely used in the therapy of diabetes in traditional folk medicine of America and Indonesia, and we previously reported the insulin sensitizing activity of the ethyl acetate fraction of AC (ACE). Aim of the study: To investigate the insulin releasing and alpha-glucosidase inhibitory activity of ACE in vitro and in vivo. Materials and methods: Insulin releasing and alpha-glucosidase inhibitory effects of different fractions from AC were detected in vitro using HIT-T15 cell line and alpha-glucosidase enzyme. Furthermore, effects of ACE orally on serum glucose were detected in fasted and glucose/amylum challenged normal mice. Results: AC and ACE increased insulin secretion in HIT-T15 cells as gliclazide did. As in vivo results, ACE (400 and 800mg/kg) significantly decreased fasting serum glucose, and suppressed the increase of blood glucose levels after 2g/kg glucose loading in normal mice. In addition, ACE as a mixed-type inhibitor inhibited alpha-glucosidase activity in vitro with an IC₅₀ of 0.41μg/ml, and 100mg/kg of it clearly reduced the increase of blood glucose levels after 5g/kg amylum loading in normal mice. Conclusions: Apart from its insulin sensitizing effect, ACE may have hypoglycemic effects via mechanisms of insulin releasing and alpha-glucosidase inhibition, and thus improves postprandial hyperglycemia and cardiovascular complications.
Agid:
777426